Interactions between HER2 and H3K4me1 were observed using PLA and silencing of HER2 significantly reduced the number of immunofluorescent foci observed in the nuclei of the EGF-treated breast cancer cells (Fig 3B and 3C). This evidence concerns the gene ERBB2 and breast carcinoma.